Glenmark Introduces Generic Cancer Treatment Drug in US
Glenmark Pharmaceuticals Inc., USA (Glenmark) has announced the imminent release of Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.
Glenmark’s Eribulin Mesylate Injection is therapeutically and bioequivalent to the reference drug, Halaven Injection, 1 mg/2 mL (0.5 mg/mL), from Eisai, Inc., with distribution set to begin in September 2025.
Based on IQVIA sales statistics for the year ending July 2025, the Halaven Injection market reached yearly sales of roughly $ 66.3 million.
Marc Kikuchi, President & Business Head for North America stated, “We are excited to reveal the introduction of Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials. This launch, as the inaugural complex generic in our lineup, signifies our commitment to expanding our product offerings in the institutional sector while emphasizing our resolve to provide quality, affordable alternatives for patients in need.
Glenmark Pharmaceuticals Limited. is a research-focused, worldwide pharmaceutical firm, operating in Branded, Generics, and OTC sectors; concentrating on therapeutic fields of respiratory, dermatology, and oncology.
Also Read: How Tensions Grew Worse between Elon Musk and Donald Trump
The organization boasts 11 top-tier manufacturing plants located on 4 continents, with activities in more than 80 nations. In Vivo/Scrip ranks Glenmark among the Top 100 Companies for R&D and Pharmaceutical Sales in 2022; meanwhile, Generics Bulletin/In Vivo positions it within the Top 50 Generics and Biosimilars Companies by Sales in 2022.
Also Read: World Youth Skills Day 2025: Youth Empowerment through AI and Digital Skills
In 2023, Glenmark’s targets for reducing Green House Gas (GHG) emissions were approved by the Science Based Target initiative (SBTi), positioning it as the second pharmaceutical company in India to reach this milestone. The organization has influenced more than 3 million lives in the past ten years through its CSR initiatives.